Contact information
Research groups
Altar M. Munis
PhD, BSc (Hons)
Postdoctoral Research Scientist
Funded by the Wellcome Trust, I am working on the development and optimisation of lentiviral gene therapy for lung diseases. In particular, my current project focuses on the treatment of surfactant protein B deficiency, a fatal autosomal recessive genetic disorder, using Sendai virus F/HN pseudotyped vectors.
Prior to joining the Gene Medicine group, I undertook my doctoral studies in gene therapy and immunology at University College London investigating the properties of phylogenetically distinct vesiculovirus glycoproteins that may have advantages over the prototypical glycoprotein from VSV Indiana strain.
Recent publications
-
A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications
Journal article
Munis AM. et al, (2021), Molecular Therapy - Methods and Clinical Development, 20, 237 - 246
-
Genome-wide Integration Site Detection Using Cas9 Enriched Amplification-free Long-range Sequencing
Journal article
HYDE S. et al, (2020), Nucleic Acids Research
-
A tool with many applications: vesicular stomatitis virus in research and medicine.
Journal article
Munis AM. et al, (2020), Expert Opin Biol Ther, 20, 1187 - 1201
-
Gene Therapy Applications of Non-Human Lentiviral Vectors.
Journal article
Munis AM., (2020), Viruses, 12
-
Use of Heterologous Vesiculovirus G Proteins Circumvents the Humoral Anti-envelope Immunity in Lentivector-Based In Vivo Gene Delivery
Journal article
Munis AM. et al, (2019), Molecular Therapy - Nucleic Acids, 17, 126 - 137